B
Balint Gergely Szabo
Researcher at Semmelweis University
Publications - 27
Citations - 143
Balint Gergely Szabo is an academic researcher from Semmelweis University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 16 publications receiving 20 citations.
Papers
More filters
Journal ArticleDOI
ESCMID COVID-19 Living guidelines: drug treatment and clinical management
Michele Bartoletti,Özlem Kurt Azap,Aleksandra Barac,Linda Bussini,Onder Ergonul,Robert Krause,José Ramón Paño-Pardo,Nicholas R. Power,Marcella Sibani,Balint Gergely Szabo,Sotirios Tsiodras,Paul E. Verweij,Ines Zollner-Schwetz,Jesús Rodríguez-Baño +13 more
TL;DR: The ESCMID COVID-19 guidelines task force was established by the ESCMIDs Executive Committee in 2019 and a small group was established, half appointed by the chair, and the remaining selected with an open call as discussed by the authors.
Journal ArticleDOI
Clinical and microbiological characteristics and outcomes of community-acquired sepsis among adults: a single center, 1-year retrospective observational cohort study from Hungary.
Balint Gergely Szabo,Rebeka Kiss,Katalin Szidonia Lenart,Bence Marosi,Eszter Vad,Botond Lakatos,Eszter Ostorházi +6 more
TL;DR: In-hospital mortality was high, and independently associated with shock, absence of fever, male gender and the need for ICU admittance, but source control and de-escalation of empirical antimicrobial therapy were protective.
Journal ArticleDOI
Laboratory parameters predicting mortality of adult in-patients with COVID-19 associated cytokine release syndrome treated with high-dose tocilizumab.
Botond Lakatos,Balint Gergely Szabo,Ilona Bobek,László Gopcsa,Gabriella Beko,Noemi Kiss-Dala,Borisz Petrik,Zsofia Gaspar,Balazs Ferenc Farkas,János Sinkó,Péter Reményi,János Szlávik,István Vályi-Nagy +12 more
TL;DR: In this article, the authors evaluated high-dose (8 mg/kg) intravenous tocilizumab administration in severe and critically ill COVID-19 adult patients fulfilling predefined strict CRS criteria.
Journal ArticleDOI
Legal framework of antimicrobial stewardship in hospitals (LEASH): a European Society of Clinical Microbiology and Infectious Diseases (ESCMID) cross-sectional international survey.
Bojana Beović,Bojana Beović,Céline Pulcini,C. Dumartin,Guillaume Béraud,Barbara Nerat,Cristina Maurel,May Doušak,Milan Čižman,Franz Allerberger,Ria Benko,Dag Berild,Robert Cunney,Martine Debacker,Aleksander Deptuła,Uga Dumpis,Oliver J. Dyar,Onder Ergonul,Balint Gergely Szabo,Cairine Gormley,Malin Grape,Thorolfur Gudnason,Philip Howard,Benedikt Huttner,Petros Ioannou,Ramona Ionescu,Emma Keuleyan,Viviane Knepper,Diamantis P. Kofteridis,Tomislav Kostyanev,Vladimir Krcmery,Botond Lakatos,Roberto Luzzati,Jaap ten Oever,Leonardo Pagani,José Ramón Paño Pardo,Mihaela Popescu,Mihaela Popovici,Mical Paul,Hege Salvesen Bix,Jeroen Schouten,Jacqueline Sneddon,Goran Stevanović,Agnes Wechsler-Fördös,Vera Vlahović-Palčevski,Peter Zarb +45 more
TL;DR: The survey showed heterogeneous legal frameworks for AMS in hospitals, and in many countries it was even lacking, and the situation may be critical in countries with poor control of antimicrobial use and resistance.
Journal ArticleDOI
ESCMID COVID-19 guidelines: update on treatment for patients with mild/moderate disease
Michele Bartoletti,OK Azap,Aleksandra Barac,Linda Bussini,Onder Ergonul,Robert Krause,Alejandro Martín-Quirós,José Ramón Paño-Pardo,Nicholas R. Power,Marcella Sibani,Balint Gergely Szabo,Sotirios Tsiodras,Ines Zollner-Schwetz,Jesús Rodríguez-Baño +13 more
TL;DR: In this paper , the authors focus on anti-viral agents, monoclonal antibodies (mAbs) and other treatment options proposed for patients with mild or moderate COVID-19 who are at the risk of hospitalization or death.